Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, August 14, 2016

press releaseMadrid, August 11th, 2016 - PharmaMar (MSE:PHM) announces that it has
received the approval from the Independent Data Monitoring Committee
(IDMC) to continue with the pivotal CORAIL study of PM1183
(lurbinectedin) in patients with platinum-resistant ovarian cancer up to
the recruitment of the 420 patients established in the protocol.
This decision is based on the futility analysis of the first 210
patients (50% of the total 420), in which the safety and efficacy of
PM1183 in this indication were evaluated.
CORAIL is a randomized Phase III Trial to evaluate the efficacy of
PM1183 in comparison with topotecan or pegylated lyposomal doxorubicin,
standard treatment of care for this pathology, in 420 patients.....